Treatment of NSCLC patients with anti-PD-1 antibodies (pembrolizumab or nivolumab) expanded the levels of effector PD-1+ CD8 T cells expressing the costimulatory molecules CD28, CD27, and ICOS [13]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.